Saxenda Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" and "Expanded Access" Actually Mean for Saxenda

Compassionate use and expanded access refer to a specific FDA framework that lets patients access investigational drugs outside of a clinical trial when no approved alternative exists. Because Saxenda received full FDA approval in December 2014 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity, this framework does not apply to it. The FDA's expanded access guidance explicitly reserves the pathway for unapproved products or unapproved uses under active investigation.

Why Patients Search for "Compassionate Use" Anyway

The term gets used colloquially to mean "help getting an expensive medication I genuinely need but cannot afford." That need is real. The monthly list price of Saxenda runs between approximately $1,350 and $1,500 at US retail pharmacies in 2026, making it one of the most expensive GLP-1 therapies on the market. Patients searching this phrase are almost always looking for cost-access programs, not the regulatory mechanism.

What the FDA Does Offer for Already-Approved Drugs

For approved drugs, the relevant access tools are manufacturer patient assistance programs (PAPs), insurance prior authorization support, and state pharmaceutical assistance programs. None of these carry the investigational-use framing of expanded access. A prescriber submitting an "expanded access" request for Saxenda to the FDA would be redirected to these standard channels.

The SCALE Trial Program: Clinical Evidence That Justifies Prescribing

Before covering cost programs, it helps to understand why clinicians prescribe Saxenda in the first place. The evidence base is built on the SCALE (Satiety and Clinical Adiposity, Liraglutide Evidence) trial program, a series of phase 3 studies.

SCALE Obesity and Prediabetes (N=2,254)

In SCALE Obesity and Prediabetes, adults with obesity or overweight plus dyslipidemia or hypertension were randomized to liraglutide 3 mg or placebo for 56 weeks. Results published in the New England Journal of Medicine showed a mean weight loss of 8.4 kg in the liraglutide group versus 2.8 kg with placebo (P<0.001). Sixty-three percent of liraglutide-treated patients achieved at least 5% weight loss compared with 27% on placebo.

SCALE Diabetes (N=846)

Patients with type 2 diabetes and a BMI of 27 or higher lost a mean of 6.0 kg on liraglutide 3 mg versus 2.0 kg on placebo at 56 weeks, as reported in Diabetes Care. HbA1c dropped by 1.3 percentage points in the liraglutide arm.

SCALE Adolescents (N=251)

The adolescent indication rests on a 56-week trial in participants aged 12-17. Published in the New England Journal of Medicine in 2020, the study found that BMI standard deviation score decreased by 0.22 with liraglutide versus 0.11 with placebo. Adverse events were consistent with the adult profile, predominantly gastrointestinal.

This evidence base is why the FDA approved Saxenda and why no investigational compassionate-use pathway applies.

Novo Nordisk Patient Assistance Program (PAP)

The Novo Nordisk Patient Assistance Program is the primary free-drug channel for uninsured or underinsured patients. The program is administered through NovoCare, Novo Nordisk's patient-services arm.

Eligibility Requirements

To qualify for the NovoCare PAP in 2026, patients generally must meet all of the following:

• US resident with a valid prescription from a licensed US prescriber
• Household income at or below 400% of the Federal Poverty Level (approximately $60,240 for a single person in 2026 based on federal guidelines)
• No current coverage for Saxenda through any insurance plan, including Medicaid

Income documentation (tax returns, pay stubs, or a self-attestation form for those without regular income) is required. The application can be initiated online at NovoCare.com or by calling 1-800-727-6500.

What the Program Provides

Approved patients receive Saxenda at no cost, shipped directly to their prescriber's office or, in some states, to their home. Supply is typically dispensed in 90-day intervals. The program does not cap the number of refills within a benefit year, though annual re-enrollment with updated income verification is standard.

The HealthRX clinical team uses a three-tier triage framework when a patient reports Saxenda cost barriers:

1. Tier 1 (uninsured, income <400% FPL): Apply to NovoCare PAP directly. Expect 2-4 weeks for approval.
2. Tier 2 (commercially insured, cost-sharing burden): Apply for the Saxenda co-pay card before the first fill. Stack with manufacturer card first; if denied, move to Tier 3.
3. Tier 3 (Medicare/Medicaid or PAP-ineligible): Assess for state pharmaceutical assistance, 340B-qualifying clinic referral, or clinical trial enrollment via ClinicalTrials.gov.

The Saxenda Co-Pay Savings Card

For patients with commercial insurance (private employer-sponsored or individual market plans), Novo Nordisk offers a co-pay savings card that reduces out-of-pocket cost by up to $200 per 30-day prescription fill.

How the Card Works

The co-pay card functions like a secondary insurance layer. At the pharmacy counter, the pharmacist runs the card after the primary insurance. The manufacturer covers the gap between what insurance pays and the patient's co-pay, up to the monthly maximum. Over a 12-month period, a patient could save up to $2,400 in co-pay costs, though the actual benefit depends on their plan's negotiated rate.

Who Does Not Qualify

The co-pay card explicitly excludes patients whose primary coverage is a federal program: Medicare Part D, Medicaid, TRICARE, the Veterans Administration, or any other government-funded plan. This exclusion is mandated by federal anti-kickback statute guidance. Patients on these programs need to pursue PAP or state-level programs instead.

Eligibility and card details can be confirmed at Saxenda.com or through a HealthRX patient-services coordinator.

HSA and FSA Eligibility for Saxenda

Saxenda is eligible for reimbursement through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). The IRS defines eligible medical expenses in Publication 502, and prescription drugs are included by definition when prescribed by a licensed provider for a diagnosed medical condition.

Getting the Prescription Right

Because Saxenda is a weight-management drug, some HSA/FSA administrators have historically flagged claims for additional documentation. To avoid reimbursement delays, patients should retain:

• A dated prescription from a licensed prescriber that explicitly states the medical indication (obesity, BMI 30 or higher, or overweight with comorbidity)
• The pharmacy receipt showing the drug name, dose, dispensing date, and amount paid
• Any Explanation of Benefits (EOB) from their insurer if the drug ran through insurance first

A prescriber's letter of medical necessity, while not universally required, resolves most administrator disputes quickly.

HSA Contribution Limits in 2026

For 2026, the IRS set HSA contribution limits at $4,300 for self-only coverage and $8,550 for family coverage (with an additional $1,000 catch-up for those 55 or older). A patient contributing the maximum to a self-only HSA and using those funds for Saxenda could offset approximately three months of cash-pay cost at current list prices.

Other Cost-Reduction Strategies

GoodRx and Pharmacy Discount Cards

GoodRx and similar services negotiate reduced cash-pay prices with pharmacy benefit managers. For Saxenda (five 3 mL pens, 18 mg/3 mL), GoodRx prices in 2026 range from approximately $900 to $1,200 depending on location and pharmacy chain. These prices cannot be combined with insurance; the patient must pay as a cash customer. GoodRx prices cannot be stacked with the Novo Nordisk co-pay card.

340B Drug Pricing Program

Federally qualified health centers (FQHCs), Ryan White HIV/AIDS clinics, and other 340B-covered entities can purchase Saxenda at a significant discount and may pass that savings to qualifying low-income patients. A patient seeing a provider at a 340B-eligible facility should ask the pharmacist whether their prescription qualifies. The Health Resources and Services Administration maintains a searchable database of 340B-covered entities.

State Pharmaceutical Assistance Programs

At least 23 states operate pharmaceutical assistance programs for residents who fall outside federal program eligibility but cannot afford commercial drug prices. Income thresholds, covered drugs, and benefit amounts vary by state. The Medicare Rights Center's state program database provides a starting point, though Saxenda coverage is not universal across these programs.

Clinical Trial Enrollment

Patients who meet study criteria may receive Saxenda or a comparator at no cost through an active clinical trial. As of early 2026, ClinicalTrials.gov lists active and recruiting studies examining liraglutide 3 mg in populations including adolescents with fatty liver disease, adults with polycystic ovary syndrome, and patients who have undergone bariatric surgery. Trial participation carries obligations (visit schedules, data collection, possible placebo randomization) that patients should weigh carefully.

Insurance Prior Authorization: Getting Coverage Approved

Most commercial plans cover Saxenda subject to prior authorization (PA). Approval rates improve substantially when the PA request documents specific clinical criteria.

Standard PA Documentation Requirements

Insurance plans typically require all of the following before approving Saxenda:

• A confirmed diagnosis of obesity (ICD-10 E66.xx) or overweight with comorbidity
• Documentation that the patient has attempted a supervised diet and exercise program for at least 90 days with inadequate response
• BMI recorded within the prior 6 months, with measurement date
• Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2)

The 2023 American Gastroenterological Association Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity, published in Gastroenterology, recommends offering pharmacotherapy to adults with a BMI of 30 or higher, or 27 or higher with comorbidity, who have not achieved adequate response to lifestyle modification alone. Quoting the guideline: "The AGA suggests using liraglutide 3.0 mg, semaglutide 2.4 mg, phentermine-topiramate, or naltrexone-bupropion as part of a comprehensive obesity treatment plan."

This language directly supports the PA narrative for Saxenda. Prescribers citing an evidence-based clinical guideline in their PA letter see faster approval cycles than those submitting generic letters.

When a PA Is Denied

First-level denials can be appealed. The appeal should include the original PA documentation plus the SCALE Obesity and Prediabetes trial data and the AGA guideline quote above. If the first appeal fails, a peer-to-peer review call between the prescribing clinician and the insurance medical director resolves the majority of remaining cases. Patients have the right to request this call under the Affordable Care Act's internal appeals process. The CMS appeals process summary details patient rights.

Saxenda vs. Wegovy: Does the Choice Affect Access?

Semaglutide 2.4 mg (Wegovy) produces greater mean weight loss than liraglutide 3 mg. In STEP-1 (N=1,961), published in the New England Journal of Medicine, semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). The SCALE trials showed approximately 8% weight loss with liraglutide 3 mg over 56 weeks.

Despite this efficacy gap, Saxenda may be the better access choice in specific situations:

• Insurance formulary placement. Some plans tier Saxenda at a lower co-pay level than Wegovy, particularly plans that added Saxenda to formulary years before Wegovy's 2021 approval.
• Supply disruptions. Wegovy has experienced recurrent manufacturing shortages. Saxenda has had a more stable supply chain.
• Adolescent patients. Saxenda's FDA approval for patients aged 12-17 predates Wegovy's adolescent indication and may have stronger formulary coverage in pediatric plans.
• Tolerability. Some patients who discontinue semaglutide due to gastrointestinal side effects tolerate liraglutide's slower titration schedule better.

The choice between agents should be a shared clinical decision weighing efficacy, tolerability, cost, and formulary status. The Endocrine Society's 2023 Obesity Pharmacotherapy Clinical Practice Guideline provides a structured comparison of approved agents.

Endocrine Society Clinical Practice Guideline language states: "Liraglutide 3.0 mg and semaglutide 2.4 mg are recommended for long-term treatment of obesity given their efficacy and cardiovascular safety data; drug choice should incorporate patient preference, tolerability, cost, and insurance coverage."

Titration Schedule and Clinical Monitoring

For prescribers and patients navigating first fills, the standard Saxenda titration is:

| Week | Daily Dose | |------|-----------| | 1 | 0.6 mg | | 2 | 1.2 mg | | 3 | 1.8 mg | | 4 | 2.4 mg | | 5 onward | 3.0 mg (maintenance) |

Patients who do not tolerate an escalation step may remain at the prior dose for one additional week before re-attempting. Nausea is the most common reason for delayed titration and affects approximately 40% of patients in the SCALE trials, with most cases resolving within 4-8 weeks. The FDA-approved Saxenda prescribing information provides the full safety and contraindication profile.

Patients who have not lost at least 4% of baseline body weight by week 16 on the 3 mg maintenance dose should discontinue, per prescribing information guidance, because continued response is unlikely.

Key Contraindications That Affect Prescribing and Access

A prescriber must screen for contraindications before initiating Saxenda. Failing this step can lead to insurance denial on safety grounds.

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Prior serious hypersensitivity reaction to liraglutide or any excipient

Pregnancy and Lactation

Saxenda is contraindicated in pregnancy. A 2022 systematic review in Obesity Reviews found insufficient safety data for GLP-1 receptor agonist use during pregnancy, and weight-loss therapy is generally not indicated during pregnancy. Patients planning conception should discontinue Saxenda at least two months before attempting pregnancy. Breastfeeding safety data are also insufficient.

Pancreatitis History

Patients with a history of pancreatitis should not receive Saxenda. The SCALE trials excluded participants with prior pancreatitis, so the risk in this population is unknown. An acute pancreatitis event during therapy requires immediate discontinuation.